Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib with Capecitabine and Temozolomide in Advanced NETs
NCT02831179Phase 1Withdrawn
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Dec 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of veliparib in Neuroendocrine Neoplasm (NEN), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Maximum Tolerated Dose at 28 days. Planned start Dec 2017; status: withdrawn.
02
Drugs
veliparib
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT02831179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02831179.